Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthopediatrics (KIDS) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Orthopediatrics (KIDS) over the last 10 years, with Q3 2025 value amounting to $1.5 million.

  • Orthopediatrics' Treasury Shares rose 4469.62% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 4469.62%. This contributed to the annual value of $1.0 million for FY2024, which is 7624.91% up from last year.
  • Per Orthopediatrics' latest filing, its Treasury Shares stood at $187000.0 for Q1 2020.
  • Orthopediatrics' 5-year Treasury Shares high stood at $1.5 million for Q2 2025, and its period low was $368446.0 during Q4 2021.
  • Over the past 5 years, Orthopediatrics' median Treasury Shares value was $566311.0 (recorded in 2023), while the average stood at $727025.9.
  • The largest annual percentage gain for Orthopediatrics' Treasury Shares in the last 5 years was 959352.27% (2021), contrasted with its biggest fall of 1392.51% (2021).
  • Over the past 5 years, Orthopediatrics' Treasury Shares (Quarter) stood at $368446.0 in 2021, then rose by 9.47% to $403324.0 in 2022, then soared by 46.89% to $592453.0 in 2023, then skyrocketed by 76.25% to $1.0 million in 2024, then surged by 44.5% to $1.5 million in 2025.
  • Its Treasury Shares stands at $1.5 million for Q3 2025, versus $1.5 million for Q2 2025 and $1.5 million for Q1 2025.